VEGF antagonists decrease barrier function of retinal pigment epithelium in vitro: Possible participation of intracellular glutathione

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 9, 2010, Pages 4848-4855

  Miura, Yoko ^a   Klettner, Alexa ^a   Roider, Johann ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BUTHIONINE SULFOXIMINE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GLUCOSE; GLUTATHIONE; PROTEIN ZO1; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; DEXTRAN; DRUG DERIVATIVE; ENZYME INHIBITOR; FLUORESCEIN ISOTHIOCYANATE; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD EYE BARRIER; CELL CULTURE; CELL PROTECTION; CELL STRUCTURE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LONG TERM EXPOSURE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN DEPLETION; SWINE; TIGHT JUNCTION; ANIMAL; CELL MEMBRANE PERMEABILITY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BUTHIONINE SULFOXIMINE; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; DEXTRANS; ENZYME INHIBITORS; FLUORESCEIN-5-ISOTHIOCYANATE; GLUCOSE; GLUTATHIONE; RETINAL PIGMENT EPITHELIUM; SWINE; TIGHT JUNCTIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77957360007     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4699     Document Type: Article

References (53)

1. Cleary CA, Jungkim S, Ravikumar K, Kelliher C, Acheson RW, Hickey-Dwyer M. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye. 2008;22:82-86.
2. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46:726-733.
3. Fang X, Sakaguchi H, Gomi F, et al. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Acta Ophthalmol. 2008;86:800-805.
4. Bonini-Filho M, Costa RA, Calucci D, Jorge R, Melo LA Jr, Scott IU. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study. Am J Ophthalmol. 2009;147:1022-1030.
5. Gutie ́rrez JC, Barquet LA, Caminal JM, et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion. Clin Ophthalmol. 2008;2:787-791.
6. Gregori NZ, Rattan GH, Rosenfeld PJ, et al. Safety and efficacy of intravitreal bevacizumab (Avastin) for the management of branch and hemiretinal vein occlusion. Retina. 2009;29:913-925.
7. Hoeh AE, Ach T, Schaal KB, Scheuerle AF, Dithmar S. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009;247:1635-1641.
8. Kondo M, Kondo N, Ito Y, et al. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis. Retina. 2009;29:1242-1248.
9. Roh MI, Byeon SH, Kwon OW. Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema. Retina. 2008;28:1314-1318.
10. Arias L, Caminal JM, Rubio M, Pujol O, Arruga J. Retinal pigment epithelial tears after intravitreal bevacizumab injection for predominantly classic choroidal neovascularization. Eur J Ophthalmol. 2007;17:992-995.
11. Bakri SJ, Kitzmann AS. Retinal pigment epithelial tear after intravitreal ranibizumab. Am J Ophthalmol. 2007;143:505-507.
12. Carvounis PE, Kopel AC, Benz MS. Retinal pigment epithelium tears following ranibizumab for exudative age-related macular degeneration. Am J Ophthalmol. 2007;143:504-505.
13. Chan CK, Lin SG. Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment. Eur J Ophthalmol. 2007;17:674-676.
14. Ronan SM, Yoganathan P, Chien FY, et al. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2007;27: 535-540.
15. Gelisken F, Ziemssen F, Voelker M, Bartz-Schmidt KU, Inhoffen W. Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration. Eye. 2009;23:694-702.
16. Chiang A, Chang LK, Yu F, Sarraf D. Predictors of anti-VEGF associated retinal pigment epithelial tear using FA and OCT analysis. Retina. 2008;28:1265-1269.
17. Konstantinidis L, Ambresin A, Zografos L, Mantel I. Retinal pigment epithelium tears after intravitreal injection of ranibizumab for predominantly classic neovascular membranes secondary to age-related macular degeneration. Acta Ophthalmol. In press.
18. Chan CK, Meyer CH, Gross JG, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular agerelated macular degeneration. Retina. 2007;27:541-551.
19. Hasler S, Schmid MK, Becht CN. Acute anterior non-granulomatous uveitis after intravitreal injection of bevacizumab. Klin Monatsbl Augenheilkd. 2008;225:446-447.
20. Wickremasinghe SS, Michalova K, Gilhotra J, et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology. 2008;115:1911-1915.
21. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol. 2008;86:372-376.
22. Cheng CK, Peng PH, Tien LT, Cai YJ, Chen CF, Lee YJ. Bevacizumab is not toxic to retinal ganglion cells after repeated intravitreal injection. Retina. 2009;29:306-312.
23. Heiduschka P, Julien S, Hofmeister S, Bartz-Schmidt KU, Schraermeyer U. Bevacizumab (Avastin) does not harm retinal function after intravitreal injection as shown by electroretinography in adult mice. Retina. 2008;28:46-55.
24. Sharma RK, Chalam KV. In vitro evaluation of bevacizumab toxicity on a retinal ganglion cell line. Acta Ophthalmol. 2009;87:618-622.
25. Sakurai K, Akiyama H, Shimoda Y, Yoshida I, Kurabayashi M, Kishi S. Effect of intravitreal injection of high-dose bevacizumab in monkey eyes. Invest Ophthalmol Vis Sci. 2009;50:4905-4916.
26. Kaempf S, Johnen S, Salz AK, Weinberger A, Walter P, Thumann G. Effects of bevacizumab (Avastin) on retinal cells in organotypic culture. Invest Ophthalmol Vis Sci. 2008;49:3164-3171.
27. Meister A, Anderson ME. Glutathione Annu Rev Biochem. 1983; 52:711-760.
28. Miura Y, Roider J. Triamcinolone acetonide prevents oxidative stress-induced tight junction disruption of retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol. 2009;247:641-649.
29. Yanagihara N, Moriwaki M, Shiraki K, Miki T, Otani S. The involvement of polyamines in the proliferation of cultured retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1996;37:1975-1983.
30. Bailey TA, Kanuga N, Romero IA, Greenwood J, Luthert PJ, Cheetham ME. Oxidative stress affects the junctional integrity of retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2004; 45:675-684.
31. Matsuda S, Gomi F, Oshima Y, Tohyama M, Tano Y. Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci. 2005;46:1062-1068.
32. Griffith OW, Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem. 1979;254:7558-7560.
33. Weinberger AW, Thiel M, Mohammadi B, Theofylaktopoulos I, Thumann G, Walter P. Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol. 2007;144:294-296.
34. Casswell AG, Kohen D, Bird AC. Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol. 1985;69:397-403.
35. Pauleikhoff D, Löffert D, Spital G, et al. Pigment epithelial detachment in the elderly: clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol. 2002;240:533-538
36. Toroser D, Sohal RS. Age-associated perturbations in glutathione synthesis in mouse liver. Biochem J. 2007;405:583-589.
37. Teramoto S, Uejima Y, Teramoto K, Ouchi Y, Fukuchi Y. Effect of age on alteration of glutathione metabolism following chronic cigarette smoke inhalation in mice. Lung. 1996;174:119-126.
38. Klettner A, Kruse ML, Meyer T, Wesch D, Kabelitz D, Roider J. Different properties of VEGF antagonists: bevacizumab but not ranibizumab accumulates in RPE cells. Graefes Arch Clin Exp Ophthalmol. 2009;247:1601-1608.
39. Zhao X, Alexander JS, Zhang S, et al. Redox regulation of endothelial barrier integrity. Am J Physiol Lung Cell Mol Physiol. 2001;281:879-886.
40. Strange C, Gottehrer A, Birmingham K, Heffner JE. Platelets attenuate oxidant-induced permeability in endothelial monolayers: glutathione- dependent mechanisms. J Appl Physiol. 1996;81:1701-1706.
41. Ghibelli L, Coppola S, Rotilio G, Lafavia E, Maresca V, Ciriolo MR. Non-oxidative loss of glutathione in apoptosis via GSH extrusion. Biochem Biophys Res Commun. 1995;216:313-320.
42. Byeon SH, Lee SC, Choi SH, et al. Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt. Invest Ophthalmol Vis Sci. 2010;51:1190-1197.
43. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
44. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-1309.
45. Ablonczy Z, Crosson CE. VEGF modulation of retinal pigment epithelium resistance. Exp Eye Res. 2007;85:762-771.
46. Ghassemifar R, Lai CM, Rakoczy PE. VEGF differentially regulates transcription and translation of ZO-1alpha+ and ZO-1alpha- and mediates trans-epithelial resistance in cultured endothelial and epithelial cells. Cell Tissue Res. 2006;323:117-125.
47. Klettner A, Roider J. Comparison of bevacizumab, ranibizumab and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008;49:4523-4527.
48. Augustin AJ, Offermann I. Combination therapy for choroidal neovascularization. Drugs Aging. 2007;24:979-990.
49. Faghihi H, Roohipoor R, Mohammadi SF, et al. Intravitreal bevacizumab versus combined bevacizumab-triamcionlone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol. 2008;18:941-948.
50. Kaiser PK, Boyer DS, Garcia R, et al. Verteporfin photodynamic therapycombined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2009;116:747-755.
51. Wolf-Schnurrbusch UE, Brinkmann CK, Berger L, Wolf S. Effects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age-related macular degeneration. Acta Ophthalmologica. In press.
52. Spaid RF. Rationale for combination therapy in age-related macular degeneration. Retina. 2009;29:S5-S7.
53. Patel S. Combination therapy for age-related macular degeneration. Retina. 2009;29:S45-S48.